Skip to main content
. 2018 Jun 22;9(48):28903–28909. doi: 10.18632/oncotarget.25627

Figure 2. Overall survival from initiation of checkpoint inhibitor therapy in uveal (UM, N = 9) and cutaneous melanoma (CM, N = 24).

Figure 2

mOS = median overall survival, NR = not reached.